KUALA LUMPUR - The Health Ministry (MOH) has approved the registration of Xenpozyme (Olipudase alfa 20mg), to treat patients suffering from Acid Sphingomyelinase Deficiency (ASMD),.
KUALA LUMPUR, Oct 7 The Ministry of Health (MoH) has approved the registration of Xenpozyme (Olipudase alfa 20mg), to treat patients suffering from Acid Sphingomyelinase.
KUALA LUMPUR (Oct 7): The Ministry of Health (MOH) has approved the registration of Xenpozyme (Olipudase alfa 20mg), to treat patients suffering from Acid Sphingomyelinase Deficiency (ASMD), a rare genetic disease.
Health director-general Datuk Dr Muhammad Radzi Abu Hassan said that the decision
/PRNewswire/ According to Prophecy Market Insights "Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by.
COVINA, Calif., May 11, 2023 /PRNewswire/ According to Prophecy Market Insights "Rare Disease Market accounted for US$ 161.4 billion in 2020 and is estimated to be US$ 547.5 billion by 2030